Aswathi Kumar, MD
Endocrinology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 18
- 3 carriers
- Office
- 1
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
18 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kumar’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
18 of 18 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A169772 · Current
Licensed to practise in California · since 2020 · expires 2028-08-31 · University of Texas Medical Branch at Galveston.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Texas BP10052909Physician-in-Training Permit · since 2015 · expires 2018-06-23Permit TerminatedNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$25,523
Medicare paid this office $25,523 for 172 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 91 | $10,409 | $80 |
| New patient visit (45+ min) | 59 | $6,446 | $109 |
| Short return visit (20+ min) | 17 | $1,065 | $59 |
| New patient visit (30+ min) | 18 | $962 | $53 |
Who their Medicare patients are
172 Original Medicare patients in 2024. Average age 73 · Under 65 10% · 85 and older 12% · Women 71% · Also on Medicaid 81% · Health risk score 1.74. Above the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 75% · Diabetes 45% · Coronary heart disease 22% · Chronic kidney disease 20% · Atrial fibrillation 20% · Heart failure 19% · Depression 16% · Dementia 13% · Cancer 11% · COPD 10% · Stroke 10%.
The office billed $217,010, Medicare allowed $34,332 and paid $25,523; for 456 services of 16 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 172 | 456 | 73 | 1.74 | $217,010 | $25,523 |
| 2023 | 426 | 6,441 | 75 | 1.70 | $803,535 | $181,209 |
| 2022 | 325 | 3,618 | 73 | 1.55 | $470,976 | $111,880 |
| 2021 | 420 | 4,467 | 74 | 1.57 | $604,558 | $150,925 |
| 2020 | 152 | 765 | 73 | 1.82 | $133,254 | $31,332 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Injection, denosumab, 1 mg | 64 | $98,055 | None |
| Return visit (30+ min) | 293 | $51,373 | $109 |
| New patient visit (45+ min) | 100 | $13,932 | $139 |
| Long return visit (40+ min) | 16 | $2,675 | $157 |
| New patient visit (45+ min) | 19 | $2,123 | $112 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 39 | $1,973 | $29 |
| Short return visit (20+ min) | 25 | $1,849 | $71 |
| Injection of drug or substance under skin or into muscle | 67 | $1,515 | $14 |
| New patient visit (30+ min) | 12 | $888 | $74 |
| Hemoglobin a1c level | 29 | $314 | $10 |
2022: 6 services
| Injection, denosumab, 1 mg | 42 | $51,299 | None |
| Return visit (30+ min) | 229 | $33,830 | $111 |
| New patient visit (45+ min) | 109 | $15,314 | $140 |
| Short return visit (20+ min) | 28 | $2,358 | $81 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 22 | $904 | $29 |
| Injection of drug or substance under skin or into muscle | 46 | $732 | $14 |
2021: 10 services
| Injection, denosumab, 1 mg | 38 | $56,552 | None |
| Return visit (30+ min) | 228 | $46,351 | $113 |
| New patient visit (45+ min) | 132 | $19,644 | $149 |
| Long return visit (40+ min) | 36 | $5,449 | $140 |
| Influenza vaccine split virus, preservative free | 62 | $4,046 | $65 |
| Short return visit (20+ min) | 43 | $3,831 | $82 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 17 | $1,517 | $89 |
| Administration of influenza virus vaccine | 65 | $1,360 | $21 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 24 | $1,240 | $31 |
| Injection of drug or substance under skin or into muscle | 38 | $682 | $12 |
2020: 4 services
| Return visit (30+ min) | 86 | $9,969 | $101 |
| New patient visit (45+ min) | 36 | $5,101 | $142 |
| Long return visit (40+ min) | 29 | $4,012 | $138 |
| Short return visit (20+ min) | 15 | $1,136 | $71 |
Medicaid work
$1,144 in 2024
Medicaid paid $1,144 for 1,154 billed services this clinician did in 2024, up to 50 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 261 | $909 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 75 | $235 |
| Medication list documented in medical record (COA) | 164 | $0 |
| Review of all medications by a prescribing practitioner or clinical pharmacist (such as, prescriptions, OTCs, herbal therapies and supplements) documented in the medical record (COA) | 19 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 187 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 44 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 62 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 263 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 79 | $0 |
| 2024 | 1,154 | 9 | 50 | $1,144 |
Drugs they prescribed that Part D paid
$299,240
Pharmacies billed $299,240 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 607) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
341 generic and 225 brand-name prescriptions · $299,240 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prolia | 72 | $106,008 | $1,472 |
| Teriparatide | 16 | $47,635 | $2,977 |
| Tradjenta | 14 | $11,995 | $857 |
| Testosterone | 14 | $5,720 | $409 |
| Nano 2nd Gen Pen Needle | 20 | $3,457 | $173 |
See all 13 drugs
| Prolia | 72 | $106,008 | $1,472 |
| Teriparatide | 16 | $47,635 | $2,977 |
| Tradjenta | 14 | $11,995 | $857 |
| Testosterone | 14 | $5,720 | $409 |
| Nano 2nd Gen Pen Needle | 20 | $3,457 | $173 |
| Lantus Solostar | 21 | $2,670 | $127 |
| Levothyroxine | 84 | $1,242 | $15 |
| Hydrocortisone | 19 | $879 | $46 |
| Testosterone Cypionate | 18 | $638 | $35 |
| Alendronate | 56 | $520 | $9 |
| Methimazole | 45 | $391 | $9 |
| Metformin | 27 | $252 | $9 |
| Metformin Hcl Er | 13 | $245 | $19 |
Year by year
| 2024 | 607 | 233 | 0% (0) | 37% | $299,240 |
| 2023 | 1,855 | 372 | 0% (0) | 48% | $1,010,781 |
| 2022 | 1,108 | 255 | 0% (0) | 48% | $537,719 |
| 2021 | 1,332 | 289 | 0% (0) | 46% | $583,060 |
| 2020 | 785 | 175 | 0% (0) | 51% | $313,496 |
| 2019 | 459 | 53 | 0% (0) | 55% | $193,907 |
| 2018 | 41 | 11 | 0% (0) | None | $9,131 |
| 2016 | 14 | None | 0% (0) | None | $3,112 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 35 drugs
| Trulicity | 114 | $215,064 | $1,887 |
| Ozempic | 46 | $93,011 | $2,022 |
| Lantus Solostar | 99 | $64,604 | $653 |
| Novolog Flexpen | 66 | $59,911 | $908 |
| Jardiance | 42 | $57,562 | $1,371 |
| Tradjenta | 47 | $48,854 | $1,039 |
| Januvia | 33 | $46,508 | $1,409 |
| Humalog Kwikpen U-100 | 34 | $42,455 | $1,249 |
| Teriparatide | 14 | $40,772 | $2,912 |
| Prolia | 17 | $28,665 | $1,686 |
| Toujeo Solostar | 19 | $25,568 | $1,346 |
| Farxiga | 22 | $22,789 | $1,036 |
| Basaglar Kwikpen U-100 | 39 | $18,115 | $464 |
| Rybelsus | 12 | $13,511 | $1,126 |
| Tresiba Flextouch U-100 | 13 | $13,391 | $1,030 |
| Toujeo Max Solostar | 11 | $10,716 | $974 |
| Nano 2nd Gen Pen Needle | 47 | $5,311 | $113 |
| Levothyroxine | 295 | $4,709 | $16 |
| Metformin | 140 | $1,866 | $13 |
| Synthroid | 13 | $1,831 | $141 |
| Metformin Hcl Er | 68 | $1,763 | $26 |
| Alendronate | 103 | $1,755 | $17 |
| Ultra-Fine Mini Pen Needle | 16 | $1,479 | $92 |
| Liothyronine | 27 | $1,361 | $50 |
| Ultra-Fine Nano Pen Needle | 12 | $1,029 | $86 |
| Repaglinide | 23 | $995 | $43 |
| Glipizide | 53 | $621 | $12 |
| Hydrocortisone | 13 | $555 | $43 |
| Methimazole | 31 | $538 | $17 |
| Atorvastatin | 41 | $532 | $13 |
| Glimepiride | 12 | $266 | $22 |
| Prednisone | 12 | $174 | $14 |
| Rosuvastatin | 12 | $141 | $12 |
| Amlodipine Besylate | 12 | $100 | $8 |
| Hydrochlorothiazide | 12 | $45 | $4 |
2022: 25 drugs
| Trulicity | 64 | $125,962 | $1,968 |
| Novolog Flexpen | 44 | $39,962 | $908 |
| Januvia | 27 | $39,804 | $1,474 |
| Tradjenta | 33 | $38,856 | $1,177 |
| Jardiance | 20 | $35,482 | $1,774 |
| Lantus Solostar | 60 | $33,860 | $564 |
| Humalog Kwikpen U-100 | 17 | $16,238 | $955 |
| Farxiga | 16 | $13,497 | $844 |
| Tresiba Flextouch U-200 | 12 | $7,771 | $648 |
| Nano 2nd Gen Pen Needle | 34 | $5,419 | $159 |
| Basaglar Kwikpen U-100 | 12 | $4,869 | $406 |
| Levothyroxine | 193 | $3,542 | $18 |
| Synthroid | 25 | $2,553 | $102 |
| Liothyronine | 15 | $1,605 | $107 |
| Repaglinide | 17 | $983 | $58 |
| Metformin | 83 | $760 | $9 |
| Alendronate | 36 | $708 | $20 |
| Metformin Hcl Er | 31 | $669 | $22 |
| Hydrocortisone | 12 | $615 | $51 |
| Atorvastatin | 21 | $344 | $16 |
| Methimazole | 21 | $296 | $14 |
| Glipizide Er | 12 | $206 | $17 |
| Glipizide | 16 | $201 | $13 |
| Glimepiride | 31 | $196 | $6 |
| Rosuvastatin | 11 | $144 | $13 |
2021: 33 drugs
| Trulicity | 61 | $122,531 | $2,009 |
| Forteo | 11 | $68,648 | $6,241 |
| Lantus Solostar | 84 | $53,599 | $638 |
| Novolog Flexpen | 34 | $38,018 | $1,118 |
| Jardiance | 25 | $36,071 | $1,443 |
| Januvia | 26 | $35,488 | $1,365 |
| Tradjenta | 30 | $31,188 | $1,040 |
| Ozempic | 16 | $17,399 | $1,087 |
| Tresiba Flextouch U-100 | 21 | $14,476 | $689 |
| Humalog Kwikpen U-100 | 13 | $12,048 | $927 |
| Toujeo Solostar | 17 | $10,039 | $591 |
| Basaglar Kwikpen U-100 | 14 | $6,205 | $443 |
| Nano 2nd Gen Pen Needle | 41 | $5,124 | $125 |
| Levothyroxine | 214 | $4,740 | $22 |
| Synthroid | 44 | $4,560 | $104 |
| Ultra-Fine Mini Pen Needle | 30 | $3,224 | $107 |
| Repaglinide | 21 | $1,605 | $76 |
| Ultra-Fine Nano Pen Needle | 15 | $1,552 | $103 |
| Armour Thyroid | 11 | $1,219 | $111 |
| Rosuvastatin | 12 | $1,171 | $98 |
| Liothyronine | 20 | $1,161 | $58 |
| Metformin | 83 | $961 | $12 |
| Metformin Hcl Er | 59 | $671 | $11 |
| Atorvastatin | 35 | $384 | $11 |
| Alendronate | 20 | $352 | $18 |
| Glipizide Er | 15 | $351 | $23 |
| Glipizide | 27 | $249 | $9 |
| Glimepiride | 27 | $202 | $7 |
| Methimazole | 12 | $192 | $16 |
| Euthyrox | 16 | $181 | $11 |
| Amlodipine Besylate | 14 | $156 | $11 |
| Simvastatin | 12 | $152 | $13 |
| Gabapentin | 11 | $134 | $12 |
2020: 18 drugs
| Trulicity | 36 | $57,877 | $1,608 |
| Lantus Solostar | 60 | $37,970 | $633 |
| Ozempic | 29 | $24,403 | $841 |
| Victoza 3-Pak | 12 | $20,132 | $1,678 |
| Humalog Kwikpen U-100 | 15 | $18,893 | $1,260 |
| Tresiba Flextouch U-100 | 26 | $16,500 | $635 |
| Novolog Flexpen | 14 | $12,877 | $920 |
| Novolin 70-30 | 11 | $12,652 | $1,150 |
| Novolog | 15 | $8,316 | $554 |
| Basaglar Kwikpen U-100 | 11 | $3,709 | $337 |
| Levothyroxine | 114 | $2,836 | $25 |
| Ultra-Fine Nano Pen Needle | 17 | $2,228 | $131 |
| Comfort Ez Pen Needle | 12 | $1,548 | $129 |
| Synthroid | 28 | $1,335 | $48 |
| Metformin | 41 | $419 | $10 |
| Atorvastatin | 24 | $319 | $13 |
| Metformin Hcl Er | 34 | $233 | $7 |
| Lisinopril | 11 | $59 | $5 |
2019: 16 drugs
| Ozempic | 18 | $19,384 | $1,077 |
| Victoza 3-Pak | 11 | $17,450 | $1,586 |
| Lantus Solostar | 30 | $17,109 | $570 |
| Trulicity | 13 | $16,332 | $1,256 |
| Humalog Kwikpen U-100 | 22 | $14,158 | $644 |
| Victoza 2-Pak | 13 | $10,691 | $822 |
| Tradjenta | 18 | $8,009 | $445 |
| Levothyroxine | 52 | $1,142 | $22 |
| Atorvastatin | 14 | $470 | $34 |
| Fenofibrate | 12 | $454 | $38 |
| Metformin | 29 | $238 | $8 |
| 1st Tier Unifine Pentips Plus | 11 | $237 | $22 |
| Metformin Hcl Er | 15 | $203 | $14 |
| Pravastatin | 12 | $177 | $15 |
| Lisinopril | 14 | $71 | $5 |
| Pioglitazone | 14 | $50 | $4 |
Money from drug and device companies
$302 in 2019
A payment is not proof that care is biased.
| Boehringer Ingelheim Pharmaceuticals | None | $125 | 1 payment
|
| Senseonics | Eversense | $118 | 1 payment
|
| Amgen | None | $59 | 1 payment
|
See all 3 published payments
| Boehringer Ingelheim Pharmaceuticals | Meals · 2019-06-08 | None | $125 |
| Amgen | Meals · 2019-04-12 | None | $59 |
| Senseonics | Meals · 2019-03-05 | Eversense | $118 |
Professional record
- NPI
- 1801283767
- Licence
- CA A169772, MO 2018015701, TX BP10052909California A169772: Current · expires 2028-08-31Texas BP10052909: Permit Terminated
- Trained
- University of Texas Medical Branch at Galveston, 2015
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X); Internal medicine (207R00000X)
- Mailing address
- 5568 Gibraltar Dr, Pleasanton, CA, 94588
- NPI first listed
- 2015-04-18
- NPI last updated
- 2023-08-15
- NPI record certified
- 2023-08-15
This is when the NPI record was last certified, not a medical board exam.